A Phase 1 interventional study of Dexmedetomidine and Propofol in Anesthesia and Pain, sponsored by Keith M Vogt. Completed at 1 site in United States. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-18.
Sponsored by Keith M Vogt · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing dexmedetomidine in Pain — 11 open to participants now, 12 under way, 2 of them phase 3. Dexmedetomidine · Pain.
Among the 64 studies testing dexmedetomidine in Pain, this one is the 23rd largest by enrollment of the 63 interventional ones that give a count, is the only one that started in 2020, is one of 7 in phase 1, and was the 30th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →11 of the 64 studies testing dexmedetomidine in Pain are open now, in 7 countries. Recruiting first, the newest first:
Fatima Memorial Hospital · Sites in Pakistan
Ages 18–60
University Hospital, Montpellier · Sites in France
Ages 1–7
Tanta University · Sites in Egypt
Ages 40–75
Assaf-Harofeh Medical Center · Sites in Israel
Ages 4 wk+
Beni-Suef University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 9 · Phase 4 22
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 70 across the 63 interventional studies. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 64 have an industry lead sponsor. The 10 most frequent:
Keith M Vogt is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Keith M Vogt has 6 studies filed under Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing dexmedetomidine in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effects of pain on long-term memory and conditioned physiologic responses in the presence and absence of distinct intravenous anesthetics. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena The study will occur over 5 visits and involves no long-term follow up.
Purpose: Sedative-hypnotic and analgesic agents (termed "anesthetics") are routinely used during medical procedures to prevent or ease suffering, suppressing the conscious experience of pain and its encoding into memory. While overt awareness under general anesthesia is a rare clinical event, implicit memory may still form. Further, at sub-hypnotic anesthetic doses, animals show enhanced fear conditioning and humans may have enhanced amygdala activity. This motivates the investigator's study, as poorly-contextualized aversive memories are theorized to initiate anxiety-spectrum disorders, which may explain the high incidence of post-traumatic stress disorder after anesthetic awareness.
Objective: How anesthetics facilitate or inhibit poorly-contextualized aversive memories is incompletely understood, with little mechanistic work done in human subjects. Thus, there is a critical need to understand how anesthetics modulate the memory and threat response systems during painful stimulation. The overall scientific objective is to determine the memory-modulating effects of propofol, dexmedetomidine, and fentanyl in the context of periodic painful stimulation.
Aim 1: Determine how behavioral and physiologic measures of memory are modulated by pain and the individual effects of three pharmacologically distinct drugs: propofol, dexmedetomidine, and fentanyl. Hypotheses: Based on previous results, 1a) explicit memory will be significantly reduced by propofol and dexmedetomidine, but only modestly by fentanyl. Consistent with my preliminary data, 1b) priming effects will be seen for pain-paired words under all drugs. Electrodermal activity changes still occur with opioids and propofol, thus 1c) pain-related physiologic responses will persist with these two drugs but be blunted by the anti-adrenergic effect of dexmedetomidine.
Aim 2: Determine the brain structures differentially engaged in memory encoding under pain and drug conditions. Task-related functional magnetic resonance imaging (MRI) activity for behavioral measures of explicit or implicit memory will be determined, comparing pain-paired vs non-pain items across drug and no-drug datasets. Functional connectivity (FC) MRI (fcMRI) will be compared between task and drug conditions. The entire brain will be explored, but predictions for key structures follow. Hypotheses: 2a) Hippocampal activity, will be blunted by propofol and dexmedetomidine, while fentanyl will have minimal effect. 2b) Amygdala activity, responsible for physiologic responses, will parallel the predictions in 1c across drug and pain conditions. 2c) Insula activity will be greater for pain-paired items, and this will be attenuated by fentanyl > dexmedetomidine > propofol, corresponding to their anticipated analgesic effect. 2d) Pain has been shown to affect fcMRI during a cognitive task, and thus FC between the key regions in 2a-c will be reduced by all three drugs, in characteristic patterns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
Drug: Dexmedetomidine · Device: Peripheral Nerve Stimulation · Drug: Placebo
Subjects in this group will receive propofol during the drug portion of the experiment.
Drug: Propofol · Device: Peripheral Nerve Stimulation · Drug: Placebo
Subjects in this group will receive fentanyl during the drug portion of the experiment.
Drug: Fentanyl · Device: Peripheral Nerve Stimulation · Drug: Placebo
Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Also known as: Precedex
Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Also known as: Diprivan
Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Also known as: fentanyl citrate
Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
Also known as: Electric Nerve Stimulation
Crystalloid IV solution will be infused, with no active drug.
Also known as: saline, IV fluid
Explicit Memory Performance
Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection \& familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance.
Time frame: 24-hrs post-experiment
Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition
The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). The outcome is listed for the hippocampus, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate a larger difference in brain activity, with positive values indicating decreases under the drug condition, while negative Z-scores indicate increases under drug, compared to control. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.
Time frame: Immediately after each experimental item
Heart Rate Response
Heart rate changes (measured by electrocardiogram, EKG) were planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in the peak of the EKG response (R-wave), allowing calculation of instantaneous heart rate. Increases in heart rate are well-known to correlate to sympathetic nervous system activity increases.
Time frame: Immediately after each experimental item
Skin Response
Electrodermal activity (galvanic skin) response was planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in electrodermal activity, measured from the palm of subjects' hand. this well-established measure indicates sweat gland activity and is correlated to sympathetic nervous system activity increases.
Time frame: Immediately after each experimental item
| Milestone | Propofol | Dexmedetomidine | Fentanyl |
|---|---|---|---|
| Started | 30 | 29 | 33 |
| Completed | 30 | 28 | 33 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection \& familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance.
| units on a scale | Placebo Control | Propofol | Dexmedetomidine | Fentanyl |
|---|---|---|---|---|
| Explicit Memory Performance | 1.16 (0.97 to 1.34) | .51 (0.182 to 0.842) | 1.04 (0.73 to 1.35) | .98 (0.68 to 1.28) |
The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). The outcome is listed for the hippocampus, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate a larger difference in brain activity, with positive values indicating decreases under the drug condition, while negative Z-scores indicate increases under drug, compared to control. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.
| Z-score for difference | Propofol | Dexmedetomidine | Fentanyl |
|---|---|---|---|
| Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition | 3.8 | -4.9 | -5.0 |
Heart rate changes (measured by electrocardiogram, EKG) were planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in the peak of the EKG response (R-wave), allowing calculation of instantaneous heart rate. Increases in heart rate are well-known to correlate to sympathetic nervous system activity increases.
No measurements were reported for this outcome.
Electrodermal activity (galvanic skin) response was planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in electrodermal activity, measured from the palm of subjects' hand. this well-established measure indicates sweat gland activity and is correlated to sympathetic nervous system activity increases.
No measurements were reported for this outcome.
Collected over Adverse event data was collected throughout the entire study period, at 5 study visits taking place over up to 3 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Propofol | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Dexmedetomidine | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) |
| Fentanyl | 0/33 (0%) | 0/33 (0%) | 2/33 (6.1%) |
| Event | Propofol | Dexmedetomidine | Fentanyl |
|---|---|---|---|
| nauseaGastrointestinal disorders | 0/30 | 0/29 | 2/33 |
| Age, Continuous(years) | Propofol | Dexmedetomidine | Fentanyl | Total |
|---|---|---|---|---|
| Mean | 25.0 ± 6.2 | 25.6 ± 6.5 | 23.9 ± 5.0 | 24.8 ± 5.9 |
| Sex: Female, Male(Participants) | Propofol | Dexmedetomidine | Fentanyl | Total |
|---|---|---|---|---|
| Female | 14 | 15 | 16 | 45 |
| Male | 16 | 14 | 17 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Propofol | Dexmedetomidine | Fentanyl | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 3 | 7 |
| Not Hispanic or Latino | 22 | 22 | 27 | 71 |
| Unknown or Not Reported | 7 | 4 | 3 | 14 |
| Race (NIH/OMB)(Participants) | Propofol | Dexmedetomidine | Fentanyl | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 5 | 6 | 8 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 3 | 3 |
| White | 18 | 17 | 15 | 50 |
| More than one race | 0 | 2 | 4 | 6 |
| Unknown or Not Reported | 7 | 4 | 3 | 14 |
| Region of Enrollment(participants) | Propofol | Dexmedetomidine | Fentanyl | Total |
|---|---|---|---|---|
| United States | 30 | 29 | 33 | 92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Apr 2024, 44 months.
Results were first posted in Apr 2025, 11 months after primary completion.
Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 44 months is above that.
Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Propofol · Fentanyl
Keith M Vogt